Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 262471

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Nerve

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 262471

License Grant
The Company granted Licensee the right to commercialize the NUCYNTA franchise of pain products in the United States.  Pursuant to the Commercialization Agreement, Licensee assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing. The Company also agreed to provide services to Licensee, including to arrange for the supply of NUCYNTA products by the Company’s existing contract manufacturing organizations (“CMOs”) (the “Facilitation Services”).
License Property
NUCYNTA ER (Tapentadol Extended Release Tablets) and NUCYNTA IR (NUCYNTA) (Tapentadol) is an extended release version of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and for which alternate treatment options are inadequate. NUCYNTA is an immediate release version of tapentadol that is indicated for the management of moderate to severe acute pain in adults.
Field of Use
This Agreement pertains to the drug industry relating to pain management.

IPSCIO Record ID: 292673

License Grant
The Company acquired the U.S. rights to the Nucynta Franchise from Party A of Germany which required no more royalty payments due to Party A; however will continue to pay Licensee (Party B)  a royalty on sales of the Nycynta Franchise.
License Property
The Nucynta Franchise, which includes both an extended-release and an immediate release formulation of tapentadol, is supported by patents with expiries in mid-June 2025, with the potential for a six-month pediatric extension.
Field of Use
The Nucynta franchise comprises Nucynta ER (tapentadol) extended release tablets indicated to treat pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), which is severe enough to require daily, around-the-clock and long-term opioid treatment.

IPSCIO Record ID: 252896

License Grant
Licensor granted a sublicense of certain intellectual property related to NUCYNTA® ER and IR products (the Products) to Licensee for commercialization of the Products in the United States of America, the District of Columbia and Puerto Rico.
License Property
NUCYNTA® ER is an extended-release formulation of tapentadol. Tapentadol is a centrally acting synthetic analgesic. Nucynta ER is approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  Nucynta ER is also approved by the FDA for neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Field of Use
This agreement pertains to the drug industry relating to pain management.

IPSCIO Record ID: 217137

License Grant
The Licensee will be granted rights to commercialize NUCYNTA® Extended Release and NUCYNTA® Immediate Release, including certain generics authorized by the Licensor and line extensions.
License Property
Nucynta (Tapentadol) is used to help relieve moderate to severe short-term pain and is an opioid analygesic.

Nucynta is for around-the-clock treatment of pain that is not controlled by other medicines.

Field of Use
This agreement relates to the drug industry, specifically drugs used to treat pain.

IPSCIO Record ID: 28803

License Grant
Licensor granted the Company an exclusive license in the United States and its possessions and territories, with defined sub-license rights to third parties other than certain technological competitors of Licensor, to certain Licensor intellectual property rights related to the Company’s Zohydro ER product candidate.
License Property
Zohydro ER (hydrocodone bitartrate) extended release capsuls for chronic pain.

Zohydro ER is an opioid agonist, extended-release oral formulation of hydrocodone without acetaminophen, for the management of sever pain enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

IPSCIO Record ID: 3265

License Grant
The Licensor will grant the Licensee a non-exclusive, royalty-bearing future license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of Oxecta® in the United States.

The Licensee's license becomes effective January 1, 2022, approximately 23 months prior to the expected expiration of the Licensor Patent.

License Property
OXECTA is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

In June 2011, the U.S. Food and Drug Administration approved Oxecta® (oxycodone HC1 tablets) which incorporates the Aversion® technology. Oxecta® is an abuse-deterrent opioid analgesic formulation.

Field of Use
The Field of Use apply to the healthcare industry.

IPSCIO Record ID: 33525

License Grant
The Israel Company entered into this Development, Manufacturing and Commercialization Agreement with a major Chinese pharmaceutical company for the Pregabalin ER product in the Chinese territory for commercialization of the products in the territory.
License Property
The Pregabalin ER product is an extended release oral form for the treatment of neuropathic pain and epilepsy.
Field of Use
This agreement pertains to the drug industry relating to neuropathic pain and epilepsy.

IPSCIO Record ID: 29210

License Grant
The Licensee holds the exclusive worldwide marketing rights to Zenvia for certain indications pursuant to an exclusive license agreement with the Licensor, a non profit corporation.
License Property
Zenvia is a combination of two well-characterized compounds the therapeutically active ingredient dextromethorphan and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of PBA and diabetic peripheral neuropathic (DPN) pain.
Field of Use
The Licensee will be obligated to pay the Licensor up to $400,000 in the aggregate in milestones to continue to develop Zenvia for both IEED/PBA and diabetic peripheral neuropathic pain (DPN pain), assuming they are both approved for marketing by the FDA.  The Licensee is not currently developing, nor do they have an obligation to develop, any other indications under the license agreement.

IPSCIO Record ID: 4395

License Grant
The Licensor entered into a strategic alliance Agreement with the Licensor with respect to the development of oxymorphone ER, an extended release formulation of oxymorphone based on our TIMERx technology.
License Property
Oxymorphone ER is a narcotic analgesic that the Licensor is  developing with the Licensee using our proprietary TIMERx technology for twice-a-day dosing in patients with moderate to severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time.
Field of Use
Oxymorphone ER, if approved, would compete in the market for long acting, strong opioids with products such as Purdue Pharma’s OxyContin and Johnson and Johnson’s Duragesic patch.

The Licensee is an integrated specialty pharmaceutical company with a market leadership position in pain management.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 233488

License Grant
The Licensor and Chinese Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in United States and China.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
Oliceridine is an opioid drug that is under evaluation in human clinical trials for the intravenous treatment of severe acute pain.

IPSCIO Record ID: 30180

License Grant
We entered into an Asset Purchase Agreement with each of a corporation registered under the laws of England and Wales which the Company acquired all of the U.S. and Canadian rights to the Licensor's product Lazanda® (fentanyl) nasal spray and related inventory.
License Property
Lazanda® nasal spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain.

IPSCIO Record ID: 369250

License Grant
Licensor grants, as of the date of execution of this Agreement, a personal, perpetual, exclusive and nontransferable right and license under the Product Intellectual Property, to make, have made, use, offer to sell, sell and import Products in the Field in the Territory for the sole purpose of completing the Pre-Launch Marketing Activities prior to the transfer of the NDA, and, thereafter a transferable license for the sole purpose of Commercialization of the Product in the Territory.
License Property
Licensor owns certain Intellectual Property Rights related to Intravenous Tramadol HCl, the Product, and is seeking approval from the FDA for the marketing and sale of products that incorporates or is comprised of Tramadol.

The Product shall mean Intravenous Tramadol HC1.

The patent is for Intravenous Administration of Tramadol.

Field of Use
Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets.  Tramadol is used to treat moderate to severe pain in adults.

IPSCIO Record ID: 1212

License Grant
The Company signed an Agreement with the Licensor that terminated the Avinza co-promotion Agreement between the two companies and returned Avinza co-promotion rights to the Licensee.
License Property
Avinza capsules are a modified-release formulation of morphine sulfate indicated for once daily administration for the relief of moderate to severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time.

IPSCIO Record ID: 3948

License Grant
Licensor grants to Dutch Licensee under the Licensor's Technology (i) an exclusive license to develop, have developed, make, have made, use, market, have marketed, promote, have promoted, commercialize, have commercialized, exploit, import, export, sell, have sold and offer to sell the Product and (ii) a nonexclusive license to develop, have developed, make, have made, import and export the Product.

The Licensor will remain responsible for completion of the ongoing Phase 3 clinical trial for DM-1796 for the treatment of pain associated with post-herpetic neuralgia.  The Licensee will be responsible for the NDA filing and has the option to develop DM-1796 in further pain indications other than post-herpetic neuralgia.

License Property
Licensor has used its proprietary AcuForm™ gastric retentive technology to develop an oral dosage form of gabapentin known as Gabapentin GR®, and is conducting Phase III clinical development of Gabapentin GR®.

“Product” means the product known as Gabapentin GR® in the formulation and at the dosage being studied in Depomed Protocol 81-0062, “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia,” dated the 25th day of January, 2008, and any alternative strengths of such dosage form, or line extensions of such product for use within the Field.

Extending the duration of drug release within the stomach during the fed mode

6,340,475

1/22/2002

U.S.

Extending the duration of drug release within the stomach during the fed mode

6,635,280

10/21/2003

U.S.

Optimal polymer mixtures for gastric retentive tablets

6,723,340

4/20/2004

U.S.

Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage form

6,488,962

12/3/2002

U.S.

Methods of Treatment using a Gastric Retained Gabapentin Dosage

7,438,927

10/21/2008

U.S.

Field of Use
Field means the treatment or amelioration of pain, including without limitation treatment of post-herpetic neuralgia (“PHN”), pain associated with diabetic neuropathy (“DPN”), Phantom Pain and fibromyalgia.

IPSCIO Record ID: 1208

License Grant
Licensor grants an exclusive license under the Technology to Develop, manufacture, have manufactured, import, use and Commercialize Products in the Field in the Territory, including the right to conduct clinical Development of the Products outside the Territory in support of Development and Commercialization of such Products in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license under the Technology, including foreign counterparts and equivalents of patent rights to the extent any exist, to manufacture and have manufactured Products outside the Territory in order to import, use and Commercialize Products in the Field in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license to use the Trademarks to Commercialize, including to advertise, promote and distribute, the Products in the Field in the Territory.

Licensor grants an exclusive license to exploit the Domain Names in connection with the Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has developed Aversion® Technology and related products intended to deter pharmaceutical product abuse.

Aversion® Composition means a composition having a gel forming polyethylene oxide, sodium lauryl sulfate, and crospovidone.

Product A means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 7.5mg with each tablet containing the Aversion® Composition with niacin at 30mg.

Product B means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 10.0mg with each tablet containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product C means an immediate release Future Product in three tablet strengths hydrocodone bitartrate 5.0mg, 7.5mg, and 10.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product D means an immediate release Future Product [in three tablet strengths hydromorphone HCl 2.0mg, 4.0mg, and 8.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg.

Trademarks means Aversion®, Acurox™, and Acuracet™.

The patents are for Methods and Compositions for Deterring Abuse of Opioid.

Acurox®, Acuracet® (oxycodone HCI/niacin/APAP) Tablets, Vycavert® (hydrocodone bitartrate/niacin/APAP) Tablets and a fourth undisclosed opioid analgesic product candidate utilizing our proprietary Aversion® Technology.

The Licensee has an option to License in the  territory all future opioid analgesic products developed utilizing Aversion® Technology. The Agreement provides that Licensor or Licensee may develop additional opioid analgesic product candidates utilizing our Aversion® Technology and, if Licensee exercises its option to License such additional product candidates, they will be subject to the milestone and royalty payments and other terms of the Agreement.

The drug is part of a class of opioid analgesic products for treatment for moderate to severe acute pain.

The Licensor is responsible, using commercially reasonable efforts, for all Acurox® Tablet development activities through FDA approval of a 505(b)(2) NDA, for which our expenses are reimbursed to us by the Licensee. After NDA approval the Licensee will be responsible for manufacturing and commercializing Acurox® Tablets in the U.S.

Field of Use
The Field means all present and future indications, as a human therapeutic, for use of the Products for the treatment of pain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.